Dr. Rachel Pessah Pollack, an endocrinologist at NYU Langone Health, appeared on CBS Mornings to discuss a new study that found promising results for the use of GLP‑1 medications in adolescents with obesity.
The study, which was recently released, examined the effects of GLP‑1 receptor agonists—a class of drugs that mimic the hormone glucagon‑like peptide‑1—on weight loss and metabolic health in teenage patients. According to the research, participants who received the medication experienced significant reductions in body weight and improvements in related health markers.
Dr. Pollack explained that GLP‑1 drugs have already been approved for adults with type 2 diabetes and for weight management in adults, but their use in younger populations has been limited. The new findings suggest that the therapy could be a viable option for adolescents struggling with obesity.
She highlighted that the study’s outcomes were encouraging, noting that the adolescents tolerated the treatment well and reported fewer side effects than typically seen in adult trials. The research team emphasized the importance of further studies to confirm long‑term safety and effectiveness in this age group.
While the study offers hope for a new treatment avenue, Dr. Pollack cautioned that GLP‑1 medications should be considered as part of a comprehensive approach that includes diet, exercise, and behavioral support. She also noted that clinicians must weigh the benefits against potential risks when prescribing these drugs to younger patients.
<small>Source: CBS News — read the original story there.</small>